论文部分内容阅读
目的探讨介入化疗栓塞联合免疫综合治疗在晚期肾癌中的应用效果。方法选取2008年1月—2009年1月邛崃市医疗中心医院收治的晚期肾癌患者84例,根据治疗方法不同将患者分为观察组与对照组,各42例。对照组患者予以单纯动脉栓塞治疗,观察组患者予以介入化疗栓塞联合免疫综合治疗。观察两组患者的出血量、手术时间及1、3、5年的生存情况。结果两组患者出血量及手术时间比较,差异无统计学意义(P>0.05);两组患者1年生存率比较,差异无统计学意义(P>0.05),观察组患者3、5年生存率高于对照组,差异有统计学意义(P<0.05)。结论介入化疗栓塞联合免疫综合治疗在晚期肾癌中应用效果显著,可延长患者的生存时间。
Objective To investigate the effect of combined chemotherapy and embolization combined with immunotherapy in advanced renal cell carcinoma. Methods From January 2008 to January 2009, 84 patients with advanced renal cell carcinoma admitted to Qionglai Medical Center Hospital were enrolled. According to the different treatment methods, the patients were divided into observation group and control group, with 42 cases in each group. Patients in the control group were treated with simple arterial embolization, and patients in the observation group were treated with chemotherapy combined with embolization combined with immunotherapy. Two groups of patients were observed bleeding, operation time and 1, 3, 5 years of survival. Results There was no significant difference in bleeding volume and operation time between the two groups (P> 0.05). There was no significant difference in one-year survival rate between the two groups (P> 0.05) The rate was higher than the control group, the difference was statistically significant (P <0.05). Conclusion Interventional chemotherapy and embolization combined with integrated immunotherapy in advanced renal cell carcinoma in the application of a significant effect, can extend the survival time of patients.